XORTX Therapeutics
XRTX
5 hedge funds and large institutions have $136K invested in XORTX Therapeutics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.
178% more capital invested
Capital invested by funds: $49K → $136K (+$87K)
67% more funds holding
Funds holding: 3 → 5 (+2)
0.35% more ownership
Funds ownership: 0.19% → 0.53% (+0.35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$47.5K |
| 2 |
VF
Virtu Financial
New York
|
+$19.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.96K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.98K |
Top Sellers
XRTX Hedge Fund Activity: Q1 2022 in Review
5 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q1 2022, worth a combined $136K — up 178% from $49K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new XRTX positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $47.5K.
- 5 institutional investors held XORTX Therapeutics (XRTX) as of Q1 2022, up from 3 in Q4 2021.
- Funds reported $136K of XORTX Therapeutics stock for Q1 2022, up 178% quarter-over-quarter.
- 2 funds opened new XORTX Therapeutics positions in Q1 2022 and 0 closed out, a net change of +2 holders.
- The largest XORTX Therapeutics buyer in Q1 2022 was Susquehanna International Group, an estimated $47.5K added.
Based on aggregated 13F filings for Q1 2022.